IL164020A0 - A process for the preparation of amorphous hmg-coareductase inhibitors - Google Patents
A process for the preparation of amorphous hmg-coareductase inhibitorsInfo
- Publication number
- IL164020A0 IL164020A0 IL16402002A IL16402002A IL164020A0 IL 164020 A0 IL164020 A0 IL 164020A0 IL 16402002 A IL16402002 A IL 16402002A IL 16402002 A IL16402002 A IL 16402002A IL 164020 A0 IL164020 A0 IL 164020A0
- Authority
- IL
- Israel
- Prior art keywords
- preparation
- hmg
- amorphous
- amorphous hmg
- coareductase inhibitors
- Prior art date
Links
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 title abstract 3
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- 238000002360 preparation method Methods 0.000 title abstract 2
- 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 title 1
- 239000002904 solvent Substances 0.000 abstract 2
- 238000004108 freeze drying Methods 0.000 abstract 1
- 150000004677 hydrates Chemical class 0.000 abstract 1
- 239000002245 particle Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C67/00—Preparation of carboxylic acid esters
- C07C67/48—Separation; Purification; Stabilisation; Use of additives
- C07C67/52—Separation; Purification; Stabilisation; Use of additives by change in the physical state, e.g. crystallisation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines Containing Plant Substances (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/IN2002/000045 WO2003078379A1 (en) | 2002-03-18 | 2002-03-18 | AMORPHOUS Hmg-CoA REDUCTASE INHIBITORS OF DESIRED PARTICLE SIZE |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL164020A0 true IL164020A0 (en) | 2005-12-18 |
Family
ID=27840281
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL16402002A IL164020A0 (en) | 2002-03-18 | 2002-03-18 | A process for the preparation of amorphous hmg-coareductase inhibitors |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US7230120B2 (de) |
| EP (1) | EP1485343B1 (de) |
| JP (1) | JP4308021B2 (de) |
| KR (1) | KR100828653B1 (de) |
| AT (1) | ATE452871T1 (de) |
| AU (1) | AU2002247944B2 (de) |
| BR (1) | BR0215644A (de) |
| CA (1) | CA2479005C (de) |
| CZ (1) | CZ2004943A3 (de) |
| DE (1) | DE60234868D1 (de) |
| ES (1) | ES2338530T3 (de) |
| HR (1) | HRP20040967A2 (de) |
| HU (1) | HUP0500074A3 (de) |
| IL (1) | IL164020A0 (de) |
| NZ (1) | NZ535910A (de) |
| WO (1) | WO2003078379A1 (de) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7655692B2 (en) | 2003-06-12 | 2010-02-02 | Pfizer Inc. | Process for forming amorphous atorvastatin |
| CA2560252C (en) | 2004-03-17 | 2009-08-04 | Ranbaxy Laboratories Limited | Process for the production of atorvastatin calcium in amorphous form |
| WO2006038219A1 (en) * | 2004-10-05 | 2006-04-13 | Biocon Limited | Process for the preparation of amorphous fluvastatin sodium |
| KR20090033405A (ko) * | 2004-10-18 | 2009-04-02 | 테바 파마슈티컬 인더스트리즈 리미티드 | 알콜 및 케톤 및/또는 에스테르의 혼합물인 유기 용매에 아토르바스타틴 헤미-칼슘 염을 용해시키고 용매를 제거하여 비결정형 아토르바스타틴 헤미-칼슘을 제조하는 방법 |
| MX2007004722A (es) * | 2004-10-28 | 2007-06-15 | Warner Lambert Co | Procedimiento para formar atorvastatina amorfa. |
| CA2547216A1 (en) | 2005-09-21 | 2007-03-21 | Renuka D. Reddy | Process for annealing amorphous atorvastatin |
| US20070202159A1 (en) * | 2006-02-02 | 2007-08-30 | Mathur Rajeev S | Pharmaceutical composition comprising stabilized statin particles |
| US8219173B2 (en) | 2008-09-30 | 2012-07-10 | Abbott Diabetes Care Inc. | Optimizing analyte sensor calibration |
| US7834195B2 (en) | 2007-01-24 | 2010-11-16 | Apotex Pharmachem Inc. | Atorvastatin calcium propylene glycol solvates |
| US20100204195A1 (en) * | 2007-07-27 | 2010-08-12 | Cipla Limited | Pharmaceutical Compositions and Process for Making Them |
| WO2010066846A2 (en) * | 2008-12-11 | 2010-06-17 | Dsm Ip Assets B.V. | Method for the isolation of atorvastatin |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK149080C (da) * | 1980-06-06 | 1986-07-28 | Sankyo Co | Fremgangsmaade til fremstilling af derivater af ml-236b-carboxylsyre |
| FI94339C (fi) * | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi |
| HRP960313B1 (en) * | 1995-07-17 | 2002-08-31 | Warner Lambert Co | Form iii crystalline (r- (r*, r*)-2- (4-fluorophenyl) -beta-delta-hydroxy-5-(1-methylethyl) -3-phenyl-4- ((phenylamino) carbonyl -1h-pyrrole-1-heptanoic acid calcium salt (2:1) |
| HRP960312B1 (en) * | 1995-07-17 | 2001-10-31 | Warner Lambert Co | NOVEL PROCESS FOR THE PRODUCTION OF AMORPHOUS /R-(R*, R*)/-2-(4-FLUOROPHENYL)-"beta", "delta"-DIHYDROXY-5-PHENYL-4-/(PHENYLAMINO)CARBONYL/-1H-PYRROLE -1-HEPTANOIC ACID CALCIUM SALT (2 : 1) |
| SI20305A (sl) | 1999-08-06 | 2001-02-28 | LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. | Kristali natrijeve soli pravastatina |
| JP2002539108A (ja) | 1999-03-08 | 2002-11-19 | メルク エンド カムパニー インコーポレーテッド | 結晶質水和ジヒドロキシオープンアシッドシンバスタチンカルシウム塩 |
| US6646133B1 (en) * | 2000-10-17 | 2003-11-11 | Egis Gyogyszergyar Rt. | Process for the preparation of amorphous atorvastatin calcium |
| HU226640B1 (en) * | 1999-10-18 | 2009-05-28 | Egis Gyogyszergyar Nyilvanosan | Process for producing amorphous atorvastatin calcium salt |
| SI20425A (sl) | 1999-12-10 | 2001-06-30 | LEK tovarna farmacevtskih in kemi�nih izdelkov d.d. | Priprava amorfnega atorvastatina |
| CA2421018A1 (en) * | 2000-09-06 | 2002-03-14 | Merck & Co., Inc. | Dihydroxy open-acid salt of simvastatin |
| JP4234429B2 (ja) * | 2000-11-16 | 2009-03-04 | テバ ファーマシューティカル インダストリーズ リミティド | 水酸化カルシウムによる〔Ｒ（Ｒ＊，Ｒ＊）〕−２−（４−フルオロフェニル）−β，δ−ジヒドロキシ−５−（１−メチルエチル）−３−フェニル−４−〔（フェニルアミノ）カルボニル〕−１Ｈ−ピロール−１−ヘプタン酸エステルの加水分解 |
| US6777552B2 (en) | 2001-08-16 | 2004-08-17 | Teva Pharmaceutical Industries, Ltd. | Processes for preparing calcium salt forms of statins |
| WO2003004450A1 (en) | 2001-07-06 | 2003-01-16 | Ciba Specialty Chemicals Holding Inc. | Process for the preparation of intermediates useful in the synthesis of statin derivatives especially 7-amino 3,5-dihydroxy heptanoic acid derivatives, and intermediates thereof |
| HUP0401006A2 (hu) | 2001-07-06 | 2004-08-30 | Teva Pharmaceutical Industries Ltd. | Eljárás 7-amino-szin-3,5-dihidroxi-heptánsav-származékok előállítására, ezek köztitermékei és módszerek az előállításukra |
| HRP20040116A2 (en) | 2001-07-06 | 2004-10-31 | Teva Pharma | Process for the preparation of 7-amino syn 3,5-dihydroxy heptanoic acid derivatives via 6-cyano syn 3,5-dihydroxy hexanoic acid derivatives |
| EP1425287A4 (de) | 2001-08-16 | 2005-09-07 | Teva Pharma | Verfahren zur herstellung von calciumsalzformen von statinen |
| WO2003068191A1 (en) | 2002-02-14 | 2003-08-21 | Ranbaxy Laboratories Limited | Formulations of atorvastatin stabilized with alkali metal additions |
-
2002
- 2002-03-18 JP JP2003576388A patent/JP4308021B2/ja not_active Expired - Fee Related
- 2002-03-18 KR KR1020047014080A patent/KR100828653B1/ko not_active Expired - Fee Related
- 2002-03-18 NZ NZ535910A patent/NZ535910A/en not_active IP Right Cessation
- 2002-03-18 BR BR0215644-0A patent/BR0215644A/pt active Search and Examination
- 2002-03-18 AU AU2002247944A patent/AU2002247944B2/en not_active Ceased
- 2002-03-18 EP EP02717024A patent/EP1485343B1/de not_active Expired - Lifetime
- 2002-03-18 ES ES02717024T patent/ES2338530T3/es not_active Expired - Lifetime
- 2002-03-18 HU HU0500074A patent/HUP0500074A3/hu unknown
- 2002-03-18 US US10/483,553 patent/US7230120B2/en not_active Expired - Fee Related
- 2002-03-18 CZ CZ2004943A patent/CZ2004943A3/cs unknown
- 2002-03-18 HR HR20040967A patent/HRP20040967A2/hr not_active Application Discontinuation
- 2002-03-18 IL IL16402002A patent/IL164020A0/xx not_active IP Right Cessation
- 2002-03-18 CA CA2479005A patent/CA2479005C/en not_active Expired - Fee Related
- 2002-03-18 WO PCT/IN2002/000045 patent/WO2003078379A1/en not_active Ceased
- 2002-03-18 AT AT02717024T patent/ATE452871T1/de not_active IP Right Cessation
- 2002-03-18 DE DE60234868T patent/DE60234868D1/de not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| EP1485343A4 (de) | 2006-05-31 |
| HRP20040967A2 (en) | 2005-06-30 |
| JP2005520830A (ja) | 2005-07-14 |
| US7230120B2 (en) | 2007-06-12 |
| AU2002247944A1 (en) | 2003-09-29 |
| NZ535910A (en) | 2006-04-28 |
| CA2479005C (en) | 2012-05-22 |
| DE60234868D1 (de) | 2010-02-04 |
| CA2479005A1 (en) | 2003-09-25 |
| EP1485343B1 (de) | 2009-12-23 |
| EP1485343A1 (de) | 2004-12-15 |
| KR20040101279A (ko) | 2004-12-02 |
| CZ2004943A3 (cs) | 2005-02-16 |
| ES2338530T3 (es) | 2010-05-10 |
| HUP0500074A2 (hu) | 2005-05-30 |
| WO2003078379A1 (en) | 2003-09-25 |
| HUP0500074A3 (en) | 2005-07-28 |
| AU2002247944B2 (en) | 2009-05-21 |
| ATE452871T1 (de) | 2010-01-15 |
| US20040186162A1 (en) | 2004-09-23 |
| KR100828653B1 (ko) | 2008-05-09 |
| JP4308021B2 (ja) | 2009-08-05 |
| BR0215644A (pt) | 2004-12-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW200510002A (en) | Solid pharmaceutical preparation | |
| DE60239428D1 (de) | ||
| AU2003211576A1 (en) | Histone deacetylase inhibitors and process for producing the same | |
| WO2005014539A3 (en) | Pyrrole-based hmg-coa reductase inhibitors | |
| EP1684754A4 (de) | Hmg-coa-reduktase-hemmer und verfahren | |
| AU2003291356A1 (en) | Methods and compositions for treating cancer using proteasome inhibitors | |
| IL164020A0 (en) | A process for the preparation of amorphous hmg-coareductase inhibitors | |
| AU2003260345A1 (en) | 2-phenylpyridin-4-yl derivatives as alk5 inhibitors | |
| ZA200210103B (en) | HMG-CoA reductase inhibitors and method. | |
| AU2003275822A1 (en) | Methods of and apparatus for pressure-ram-forming metal containers and the like | |
| TW200638950A (en) | Dosage forms of cholesteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors | |
| AU2003277574A1 (en) | Depolymerization process | |
| AU2003269421A1 (en) | Hiv-integrase inhibitors, pharmaceutical compositions, and methods for their use | |
| AU2003250172A1 (en) | Compositions comprising hmg-coa reductase inhibitor | |
| TW200509993A (en) | Process for forming amorphous atorvastatin | |
| WO2007075870A3 (en) | Processes for taxane derivatives and intermediates useful therein | |
| AU2003253773A1 (en) | Methods and apparatus for forming anastomotic sites | |
| TW200724688A (en) | Process for producing atorvastatin, pharmaceutically acceptable salts thereof and intermediates thereof | |
| BRPI0417138A (pt) | n-alquil-pirroles como inibidores de hmg-coa-redutase | |
| BRPI0506865A (pt) | inibidores de hmg-coa redutase inusitados, baseados em imidazóis | |
| WO2007011405A3 (en) | Device and method of use for detection and characterization of microorganisms and microparticles | |
| IL157597A0 (en) | Diaminoquinazoline esters for use as dihydrofolate reductase inhibitors | |
| WO2007022044A3 (en) | Combination of organic compounds | |
| WO2007010013A3 (en) | Combination comprising a pyrimidylaminobenzamides and a flt-3 inhibitor for treating proliferative diseases | |
| AU2003208275A1 (en) | Trojan inhibitors, method for the production and use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| KB | Patent renewed | ||
| MM9K | Patent not in force due to non-payment of renewal fees |